drugset / Trial / NCT03101111
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
Phase 2
Completed
34 enrolled
Themis Bioscience GmbH
Walter Reed Army Institute of Research (WRAIR) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed. MV-CHIK will be compared to the commercially available MMR vaccine. 80% of the subjects will receive MV-CHIK; 20% will receive MMR vaccine.
Timeline
- Start
- 2017-08-09
- Primary completion
- 2019-04-02
- Completion
- 2019-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MMR vaccine | Vaccine | 1000 unknown | — |
| Comparator | MMR vaccine | Vaccine | 12500 unknown | — |
| Subject | MV-CHIK | Vaccine | 500000 unknown | Intramuscular |